NCT05095168View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions

PNH

Interventions

DRUG

CAN106

CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.

DRUG

Placebo

placebo

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors

lead

CARE Pharma Shanghai Ltd.

INDUSTRY

NCT05095168 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects | Biotech Hunter | Biotech Hunter